Texas A&M Football

Cover Story: Dangerous test awaits Mike Elko's Aggies at Jordan-Hare

Texas A&M and Texas have waited 13 long years to renew their historic rivalry, so they can wait another week because the Aggies cannot be caught looking ahead. With everything still to play for, Mike Elko & Co. must be focused as they travel to Auburn for a Saturday night clash.
By Billy Liucci
November 18, 2024
9.6k Views
Discuss
Story Poster

Mike Elko did something I'm not sure I've seen on Saturday night prior to the Ags' November non-conference date with New Mexico State.

Twenty-six Aggies were honored on Senior Day.

You know where I'm going with this.

Normally, Senior Day is held on the final home Saturday of the season.

This fall, the Ags' final game at Kyle Field takes place in two weeks. You know the opponent.

To continue reading, you must be a TexAgs Premium subscriber.
Get Premium for $1
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial
Discuss
Tags
Collin Klein D.J. Durkin Mike Elko 12th Man Foundation Hugh Freeze Gus Malzahn Nick Marshall Tre Mason Cover Story Johnny Manziel Jimbo Fisher Brian Kelly
Show All
Shane Beamer Jarquez Hunter Payton Thorne KeAndre Lambert-Smith Cam Coleman Diego Pavia Texas A&M vs. Texas Texas A&M vs. New Mexico State Texas A&M at South Carolina Texas A&M at Auburn Amari Daniels Le'Veon Moss Marcel Reed Theo Melin-Öhrström Tre Watson Football Texas A&M Texas LSU South Carolina Vanderbilt Tennessee Auburn Florida State New Mexico State Ole Miss 2024
SPONSORED BY
12th Man Foundation
More Football
See All →
Josh Pate says undefeated Aggies cannot look past trip to Missouri
By David Nuño
Charean Williams provides thoughts on A&M's November opponents
By David Nuño
A&M expects Mizzou's offense to be tailored differently around Zollers
By Olin Buchanan
Press Conference: No. 3 Aggies travel to face No. 19 Mizzou in CoMo
By TexAgs
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.